Analyst Finds Perrigo 'Still Attractive' As Take Out Target

Loading...
Loading...

Despite Perrigo Company plc Ordinary Shares PRGO's rejection of a $205 a share offer, the company remains an attractive takeover target, an analyst said Wednesday.

"Either now or in the future, we can't rule out broader strategic interest in Perrigo," said J.P. Morgan's Chris Schott, who maintained an Overweight rating and $215 target.

Perrigo, an Ireland-based generic drug-maker, said Tuesday that Mylan NV MYL's $29 billion offer undervalues Perrigo, with its recent $4.5 billion acquisition of Omega Pharma.

Perrigo gained 3 percent recently to $198.63.

Schott noted the generic drug sector is "rapidly consolidating" and estimated that Perrigo is worth $180 a share on a "stand-alone basis" -- his $215 price target includes $35 a share to account for "M&A optionality."

Although a higher bid from Mylan would be "unsurprising" according to Schott, Teva Pharmaceutical Industries Ltd.'s TEVA recent $40 billion bid for Mylan makes that less likely.

Perrigo managers declined comment in a conference call Tuesday on broader strategic interest in their company. "But they did acknowledge some logic behind a merger with a larger organization," Schott concluded.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechPrice TargetReiterationM&AAnalyst RatingsGeneralbiotech M&AChris SchottJPMorganPerrigo
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...